|Molecular Prevention and Therapy of Human Diseases - CNRS FRE2849|
|HEAD||Dr GUISO Nicole / email@example.com|
|MEMBERS||Dr BEDOUELLE Hugues / BOUCHEZ Valérie / Dr CARO Valérie / GUILLOT Sophie
LISOVA Olesia / Dr NJAMKEPO Elisabeth
Research on vaccine preventable diseases is the major theme of our unit. Our objective is to evaluate the consequences of extensive vaccination of human populations on the microbe targeted by the vaccine, the ecosystem and the human population in order to propose adapted strategies of prevention and new therapeutic tools to face some of these consequences.
Our unit harbors the National Center of Reference for Whooping Cough and other bordetellosis http://www.pasteur.fr/sante/clre/cadrecnr/bordet-index.html.
The Bordetella team studies the bacterial determinants involved in the pathogenicity of the bacteria from the Bordetella genus, the regulation of the expression of these determinants, the immune responses that they induce in the host human or animal after infection or vaccination, the spatio-temporal evolution of the bacteria and the development of new therapeutical and diagnostic tools. The results of 2006 were, after the development of microarrays, the demonstration of the temporal evolution of B. pertussis population in France with a decrease in genetic diversity essentially due to loss of genes and pseudogenes, most them being flanked by insertion sequences; a similar evolution in Argentina, a country with similar history of long-term mass vaccination with the same whole-cell vaccine; the analysis of a prospective study of infants (< 6 months) with laboratory confirmed pertussis and their household and non household contacts demonstrating that household members are responsible for transmission of B. pertussis to infants in 76-83 % of cases and that vaccination of adolescents and adults in close contacts with young infants may eliminate up to 66 % of infant pertussis if coverage high. Teaching, training scientists from the net of the Institut Pasteur, help in case of epidemics and public health activities, were pursued.
The protein and antibody engineering team is studying the mechanisms of neutralization of infectious agents by antibodies at the molecular and atomic levels. In 2006, the mechanisms of recognition between a neutralizing monoclonal antibody and the envelope glycoprotein of the dengue virus were characterized. The fine mapping of its epitope and paratope by site-directed mutagenesis and the introduction of the epitope residues in the envelope proteins from other flaviviruses have enabled to verify that the mapped epitope was complete, show that it is discontinuous, explain the absence of recognition of other flaviviruses. A simple and specific ELISA assay for the detection of the dengue infections, and for which all the reagents can be produced in bacteria at low levels of biosafety was developed. The design and construction of reagentless fluorescent biosensors were pursued.
|More informations on our web site|
|Publications 2006 of the unit on Pasteur's references database|
Activity Reports 2006 - Institut Pasteur
If you have problems with this Web page, please write to firstname.lastname@example.org